Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on September 21, 2016. The report discloses a material event regarding the company's clinical development program for NSI-189, a novel neurogenic small molecule intended for the treatment of major depressive disorder.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a clinical trial milestone.
Material Changes
The primary material event reported is the achievement of over 50% enrollment in the company's Phase 2 clinical trial for NSI-189. This represents a significant progression in the drug's development timeline compared to the prior period.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the enrollment milestone. The filing does not contain updated financial guidance, specific risk factors, or details on contingencies beyond the standard disclosure of the clinical trial status. The attached press release (Exhibit 99.01) contains the full details of the announcement.
Key Facts for Investor Verification
- Confirm the total target enrollment number for the Phase 2 trial to assess the remaining timeline.
- Review the attached press release (Exhibit 99.01) for details on the study design and patient demographics.
- Verify the company's current cash runway in subsequent filings (e.g., 10-Q or 10-K) as this 8-K does not disclose liquidity status.
- Monitor future updates on the completion of enrollment and the anticipated timeline for data readout.